Overview
Definition:
Neuroblastoma is a malignant tumor of the sympathetic nervous system, arising from neural crest cells
It is one of the most common solid tumors of infancy and childhood, accounting for approximately 15% of all pediatric cancer deaths.
Epidemiology:
It most commonly occurs in infants and young children, with a median age of diagnosis around 18 months
There is a bimodal age distribution, with a peak in the first two years of life and another smaller peak in children aged 4-6 years
It is rare in children over 10 years of age
Incidence is approximately 10-12 cases per million children worldwide.
Clinical Significance:
Understanding neuroblastoma staging is critical for accurate prognostication, treatment planning, and risk stratification
Staging guides treatment intensity, impacting survival rates and long-term outcomes
Early and accurate staging is paramount for effective management in pediatric oncology.
Clinical Presentation
Symptoms:
Abdominal mass
Bone pain
Fever
Irritability
Weight loss
Pallor
Proptosis or periorbital ecchymosis ("raccoon eyes")
Horner's syndrome (ptosis, miosis, anhydrosis)
Symptoms related to metastatic disease, such as respiratory distress (mediastinal tumors) or spinal cord compression (paraspinal tumors).
Signs:
Palpable abdominal mass, often firm and non-tender
Hepatomegaly
Bone tenderness on palpation
Hypertension
Ocular abnormalities (dilated pupils, unequal pupils)
Lymphadenopathy.
Diagnostic Criteria:
Diagnosis is confirmed by biopsy demonstrating characteristic histology of neuroblastoma and elevated urinary catecholamine metabolites (vanillylmandelic acid [VMA] and homovanillic acid [HVA])
Staging is based on imaging and biopsy findings according to established international protocols.
Diagnostic Approach
History Taking:
Detailed history focusing on duration and progression of symptoms, family history of neuroblastoma or other cancers, and developmental milestones
Inquire about feeding difficulties, changes in bowel/bladder habits, and neurological deficits.
Physical Examination:
Thorough physical examination including assessment of general condition, vital signs, abdominal palpation for masses or organomegaly, neurological assessment for any signs of compression or involvement, and examination of the eyes and skin for characteristic findings.
Investigations:
Complete blood count (CBC) with differential
Comprehensive metabolic panel (CMP)
Urinary catecholamines (VMA and HVA)
Serum ferritin and lactate dehydrogenase (LDH) as tumor markers
Imaging: Ultrasound of abdomen to detect primary tumor and metastases
CT or MRI of chest, abdomen, and pelvis to define tumor extent and involvement of adjacent structures
MIBG (metaiodobenzylguanidine) scintigraphy is crucial for detecting primary tumor and metastatic sites, especially bone and soft tissue involvement
Bone marrow aspirate and biopsy for assessment of bone marrow infiltration
Genetic analysis of tumor tissue (e.g., MYCN amplification) for risk stratification.
Differential Diagnosis:
Wilms tumor (nephroblastoma)
Other pediatric renal tumors
Lymphoma
Sarcomas
Benign adrenal masses
Hepatic tumors
Ovarian or testicular tumors
Germ cell tumors.
Staging System Inrgss
Inrgss Overview:
The International Neuroblastoma Risk Group Staging System (INRGSS) is the current standard for staging neuroblastoma
It combines clinical staging (based on imaging findings) with biological factors.
Inrg Imaging Prognostic Stage Iig:
Stage IIG is defined by the presence of specific adverse imaging features that predict a higher risk of relapse or progression
These include tumor infiltration of: Infiltration of the root sleeve of the spinal nerve
Intraspinal extension
Encapsulation of the tumor with displacement of the kidney or major vessels
Division of the superior mesenteric artery or celiac axis
Contact with the aorta or vena cava
Infiltration of the porta hepatis
Displacement of the bowel
Encapsulation of the vena cava or aorta
Invasion of the portal vein or hepatic veins.
Interpretation:
The INRGSS stage is determined by combining the International Neuroblastoma Staging System (INSS) stage (which is a surgical staging system) with MYCN amplification status and other biological markers
However, for the purpose of understanding basic staging, focusing on the imaging prognostic criteria is key for examination preparation.
Risk Stratification And Prognosis
Mycn Amplification:
MYCN gene amplification is a powerful adverse prognostic factor, associated with aggressive disease and poorer outcomes
Its presence significantly impacts treatment decisions and risk stratification.
Age At Diagnosis:
Younger age at diagnosis (under 18 months) generally confers a better prognosis compared to older children
This is a critical factor in risk group assignment.
Stage And Biology:
Combination of stage (INRGSS/INSS), MYCN status, ploidy, and other biological markers (e.g., DNA index, ferritin, LDH) defines risk groups: low, intermediate, and high risk
Low-risk disease has excellent survival, while high-risk disease has a significantly poorer prognosis despite aggressive therapy.
Factors Affecting Prognosis:
Tumor location
Presence of metastases
Histological differentiation
Chromosomal abnormalities
Response to initial therapy
Presence of specific genetic mutations.
Key Points
Exam Focus:
Understand the INRGSS imaging prognostic criteria for Stage IIG
Recognize MYCN amplification as a critical adverse prognostic factor
Differentiate between INSS and INRGSS staging
Know the common age groups affected and typical presentation sites.
Clinical Pearls:
Always consider neuroblastoma in any infant or young child presenting with an abdominal mass or unexplained symptoms like fever, bone pain, or pallor
Urinary catecholamines are essential diagnostic markers
MIBG scan is key for staging and assessing metastatic disease.
Common Mistakes:
Confusing INSS (surgical staging) with INRGSS (imaging-based staging)
Underestimating the importance of MYCN amplification in risk stratification
Failing to consider neuroblastoma in the differential diagnosis of common pediatric symptoms.